AJP - Heart Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol (March 28, 2008). doi:10.1152/ajpheart.00873.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/6/H2497    most recent
00873.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saeedi, R.
Right arrow Articles by Allard, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saeedi, R.
Right arrow Articles by Allard, M. F.
Submitted on July 25, 2007
Accepted on March 26, 2008

Metabolic Actions of Metformin in the Heart Can Occur by AMPK-independent Mechanisms

Ramesh Saeedi1, Hannah L Parsons2, Richard B Wambolt3, Kim Paulson1, Vijay Sharma1, Jason R. B. Dyck4, Roger W Brownsey5, and Michael F. Allard6*

1 Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
2 Pathology, UBC, Vancouver, Canada
3 Pathology & Laboratory Medicine, UBC / St Paul's Hospital, Vancouver, Canada
4 Pediatrics, University of Alberta, Edmonton, Canada
5 Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada
6 McDonald Research Laboratories/iCAPTURE Centre, University of British Columbia, Vancouver,, Canada

* To whom correspondence should be addressed. E-mail: mallard{at}mrl.ubc.ca.

The metabolic actions of the anti-diabetic agent, metformin, reportedly occur via activation of AMP-activated protein kinase (AMPK) in the heart and other tissues, in the presence or absence of changes in cellular energy status. In this study, we tested the hypothesis that metformin activates AMPK and alters metabolism in heart muscle without alterations in energy status. Fatty acid oxidation and glucose utilization (glycolysis and glucose uptake) were measured in isolated working hearts from halothane -anesthetized male Sprague-Dawley rats and in cultured heart-derived H9c2 cells in the absence or in the presence of metformin (2mM). Fatty acid oxidation and glucose utilization were significantly altered by metformin in hearts and H9c2 cells. AMPK activity was not measurably altered by metformin in either model system and no impairment of energetic state was observed in the intact hearts. Further, inhibition of AMPK by Compound C, a well recognized pharmacological inhibitor of AMPK, or overexpression of a dominant negative form of AMPK failed to prevent the metabolic actions of metformin in H9c2 cells. Exposure of H9c2 cells to inhibitors of p38 mitogen activated protein kinase (p38 MAPK) or protein kinase C (PKC), partially or completely abrogated metformin-induced alterations in metabolism in these cells, respectively. Thus, the metabolic actions of metformin in heart muscle can occur independent of changes in AMPK activity and may be mediated by p38 MAPK- and PKC-dependent mechanisms.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.